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The aim of the current study was to determine the impact and interaction of important influ-
encing factors on the fraction of exhaled nitric oxide (FeNO).
FeNO was measured in a population-based sample of 1250 middle-aged subjects from the
KORA F4 cohort (Augsburg, Germany). Analysis of covariance models was performed including
the factors age, height, FVC, FEV1, sex, current smoking status, recent respiratory tract infec-
tion, and respiratory allergy.
Geometricmean (SDas factor; 95%confidence intervalas factor)FeNOwas13.9 (1.9; 1.033)ppb.
FeNOsignificantlydependedonage,height, smoking, infectionandallergy. Smoking reducedFeNO
by 21%, while infection and allergy led to increases by 9 and 11%, respectively. Increases in age bynd Outpatient Clinic for Occupational, Social and Environmental Medicine, LMU, Ziemssenstr. 1,
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bsolute numbers and percentages,10years and inheight by10cmwereassociatedwith increases of FeNOby15and 10%, respectively.
Non-smokers demonstrated independent multiplicative superposition of factors affecting FeNO
while the effect of allergy was virtually eliminated in smokers without infection.
We conclude that in middle-aged non-smokers the effects of infection, age and height can be
easily taken into account and do not significantly disturb the effect of respiratory tract allergies
on FeNO. In current smokers, however, effects were heterogeneous and information on smoking
intensity seems to be useful for better adjustment.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Since the discovery that the fraction of exhaled NO (FeNO)
is increased in patients with asthma,1 much work has been
done to establish FeNO as a noninvasive marker of bronchial
inflammation and a useful readout particularly in allergic
asthma.2 Naturally, the diagnostic applicability of FeNO
depends on the availability of reference values that
adequately take into account the major factors affecting
FeNO. Within the last years a number of publications have
provided such reference values on the basis of population
samples of adults or children.3e8
Although the available data do not fully agree on the
panel of factors influencing FeNO, important factors besides
atopy have clearly been identified, including age, height,
sex, smoking and respiratory tract infection.4,9e12 Regarding
practical implications the question arises to which extent
these factors numerically affect FeNO and whether some of
them are even capable of extinguishing the information on
airway allergic inflammation carried by FeNO. A recent
study13 demonstrated that major factors such as smoking
and respiratory tract infection were associated with changes
in FeNO according to a law of independent superposition,
which allowed taking account of these factors in a simple
manner. However, the population studied predominantly
comprised young subjects, with a mean age of 34 years. As
differences in the cumulative exposure to noxious
substances including cigarette smoke and possible subse-
quent alteration of the respiratory epithelium may be more
pronounced with increasing age the question arises whether
the superposition of effects also applies in subjects of higher
age and whether it is comparable, both qualitatively and
quantitatively, to that found in younger subjects.
Based on these considerations the present study identi-
fied the relevant factors influencing FeNO in a large pop-
ulation-based sample of middle-aged subjects.study cohort.
Women
656 (52.5)
51.5  5.6 (
163.6  6.2
71.5  14.1
3.64  0.62
2.84  0.51
140 (21.3)
110 (16.8)
86 (13.1)
or mean values and standard devMaterial and methods
Study population
Data are based on the KORA F4 study (2006e2008), a follow-
up study of the KORA S4 survey conducted in 1999e2001. The
KORA S4 study population was recruited from the region
of Augsburg in the South of Germany. The study design,
samplingmethod, and data collection have been described in
detail elsewhere.14 Briefly, in the KORA S4 survey of the 6640
men and women aged 25e74 years that were randomly
selected from population registries, 4261 participated in the
baseline examination, out of which 3080 (72%) also took part
in the follow-up examination conducted between 2006e08.
Persons were considered ineligible for follow-up if they had
died during follow-up, moved too far outside the study area,
or were lost to follow-up. The current study was restricted to
1250 subjects agedbetween 41 and 63 yearswithout intakeof
inhaled or systemic corticosteroids (nZ 32) or missing values
on any of the analytical variables. All study participants gave
written informed consent and the study was approved by
the ethics committee of the Bavarian Medical Association
(Table 1).
Assessments
Body weight and height were determined by standardized
anthropometry, spirometry was performed using ATS/ERS
recommendations15 by a pneumotachograph-type spirom-
eter (Masterscreen, Cardinal Health, Wu¨rzburg, Germany).
At least two acceptable and reproducible measurements
were required. The spirometer was calibrated at least daily
using a 1L-calibration pump.
FeNO was determined from controlled expirations at
a flow rate of 50 mL/s in accordance with ATS/ERS recom-
mendations16 (NIOX 2.0, Aerocrine, Sweden). At least threeMen
594 (47.5)
41e63) 51.7  5.9 (41e63)
176.9  6.3
87.7  15.0
(120.6  15.8) 5.03  0.80 (112.0  13.8)
(110.7  16.9) 3.89  0.71 (107.9  16.4)
152 (25.6)
79 (13.3)
70 (11.8)
iations are given.
Table 2 Parameter estimates from the full ANCOVA model including interactions (R2 Z 0.20).
Parameter
(log10)
SEM
(log10)
p-value 95%CI
(log10)
þ95%CI
(log10)
Factor
on FeNO
D% of FeNO
Intercept 0.06243 0.22065 0.777275 0.37045 0.49531 e e
Sex (male) 0.01297 0.01117 0.246020 0.00895 0.03488 0.971 3%
Age per 10 years 0.06152 0.01260 0.000001 0.03680 0.08624 1.152 þ15%
Height per 10 cm 0.04495 0.01150 0.000098 0.02239 0.06751 1.109 þ11%
Respiratory allergy 0.04326 0.01050 0.000040 0.02266 0.06386 1.105 þ11%
Smoking 0.10276 0.01105 <0.000001 0.12444 0.08108 0.789 21%
Respiratory infection 0.04811 0.01097 0.000013 0.02659 0.06964 1.117 þ12%
Sex (male)  Smoking 0.01968 0.00824 0.017026 0.03584 0.00352 0.956 4%
Infection  Smoking 0.02431 0.01098 0.026932 0.00278 0.04584 1.058 þ6%
FeNO and influencing factors 715acceptable and reproducible maneuvers were required. Final
FeNO values were calculated as arithmetic mean of these
values. The NO analyzer was calibrated every twoweeks using
a certified calibration gas (Linde, Germany) according to the
manufacturer’s recommendations. Ambient air pressure,
temperature, humidity and ambient NO levels were recorded
for each measurement.
Information on the presence of current respiratory tract
infection (during the last 3 weeks), respiratory allergy (i.e.
physician-diagnosed asthma or symptoms of respiratory
allergy including hay fever within the last 3 days) as well as
current smoking status were assessed by a standardized
questionnaire.
Data analysis
Subjects currently using inhaled or oral corticosteroids
were excluded because of the effect of these drugs on
FeNO values. The data of the remaining sample (nZ 1250)
were used for analysis. For data description arithmetic
mean values and standard deviations (SD) were used or
geometric mean values and standard deviations in case of
FeNO values. Geometric SD was expressed as a factor for
multiplication with the geometric mean.
Statistical analysis was performed by linear models based
on analysis of covariance (ANCOVA) using log-transformed
FeNO values as the dependent variable. The factors included
in theanalysis comprisedage,height, FVC,FEV1 as continuous
variables, and sex, current smoking status, respiratory tract
infection and respiratory allergy as categorical variables.
Initially these main factors were used without interactionsTable 3 Parameter estimates from the ANCOVA model includin
Parameter
(log10)
SEM
(log10)
Intercept 0.00723 0.15245
Age per 10 years 0.06071 0.01219
Height per 10 cm 0.04366 0.00763
Respiratory allergy 0.04625 0.01037
Cigarettes smoked per day 0< n 10 0.00965 0.02136
10< n 20 0.07758 0.02022
20< n 0.14101 0.02994
Respiratory infection 0.03693 0.00962and then the whole set of pairwise interactions between
those factors that were statistically significant was added.
The panel of interactionswas then reduced by excluding non-
significant interactions in a stepwise manner according to
their p-value. The procedure followed was similar to that
used in a previous study13 in order to achieve comparability
between the results. Statistical significance was assumed for
p < 0.05. Analyses were performed using the commercially
available software STATISTICA (StatSoft Inc, USA).
Results
The geometric mean (SD as factor; 95% confidence interval
as factor) FeNO value in the whole population (n Z 1250)
was 13.9 (1.9; 1.033) ppb. In the presence of respiratory
allergy (12.5%) FeNO was 16.5 (2.1; 1.129) ppb, and in the
absence 13.6 (1.8; 1.036) ppb. Current smokers (23.4 %)
showed geometric mean (SD; 95% CI) FeNO of 9.0 (1.9;
1.075) ppb, and current non-smokers of 15.9 (1.8;
1.037) ppb. After respiratory tract infection (15.1%) values
were 15.3 (1.9; 1.100) ppb, and in the absence of infection
13.7 (1.9; 1.038) ppb.
According to the final ANCOVA of log10FeNO model
including second-order interactions, FeNO was dependent
on height, age, the presence of respiratory allergy, respi-
ratory tract infection and smoking status (p < 0.0005 each).
The analysis of interactions revealed all of them as not
being significantly different from zero, except for an
interaction between sex and smoking, as well as between
infection and smoking. The parameters of this additive
regression model are shown in Table 2. This table alsog smoking intensity (R2Z0.21).
p-value 95%CI
(log10)
þ95%CI
(log10)
Factor
on FeNO
D% of
FeNO
0.962188 0.30632 0.29186 e e
0.000001 0.03679 0.08464 1.150 þ15%
<0.000001 0.02870 0.05863 1.106 þ11%
0.000009 0.02590 0.06660 1.112 þ11%
0.651371 0.03225 0.05156 1.022 þ2%
0.000131 0.11725 0.03791 0.836 16%
0.000003 0.19975 0.08227 0.723 28%
0.000130 0.01805 0.05581 1.089 þ9%
Table 4 Parameter estimates from the ANCOVA model without interactions (R2 Z 0.19).
Parameter
(log10)
SEM
(log10)
p-value 95%CI
(log10)
þ95%CI
(log10)
Factor
on FeNO
D% of FeNO
Intercept 0.08891 0.15447 0.565011 0.21414 0.39195 e e
Age per 10 years 0.06096 0.01239 0.000001 0.03665 0.08528 1.151 þ15%
Height per 10 cm 0.04315 0.00774 <0.000001 0.02797 0.05833 1.104 þ10%
Respiratory allergy 0.04406 0.01053 0.000031 0.02341 0.06472 1.107 þ11%
Smoking 0.11912 0.00834 <0.000001 0.13549 0.10276 0.760 24%
Respiratory infection 0.03678 0.00976 0.000173 0.01763 0.05592 1.088 þ9%
716 S. Karrasch et al.includes re-transformed parameters which correspond to
multiplicative factors with regard to FeNO as well as the
respective alteration in percent.
If smoking intensity (i.e. self-reported number of ciga-
rettes smoked per day) was used instead of the binary
smoking variable, the interactions between smoking and
sex as well as between smoking and infection disappeared.
The other factors were virtually unaffected by this. The
results of this analysis are shown in Table 3.
Finally, Table 4 shows the model obtained with the
binary smoking variable when interactions were omitted.
The estimates of the reduced model (Table 4) were well
within the 95% confidence limits of the full model (Table 2).
The corresponding formula for the calculation of FeNO by
the model without interactions is:
FeNO½ppbZ13:405 1:151ðage½y50Þ=10  1:104ðheight½cm170Þ=10
 1:107allergy  0:760smoking  1:088infection
(Here, the variables allergy, smoking and infection are set to
1 if the respective factor is present, otherwise they are set to
zero.)
Fig. 1 shows the geometric mean values and SD of FeNO
for the different combinations of binary categories and
illustrates the independent superposition of the binary
factors as well as the deviation from this finding in smokers
with or without respiratory allergy. Similarly, the positive
correlation between FeNO and age is shown in Fig. 2,
after adjusting for allergy, infection, smoking and height.
Regarding its effect on FeNO, a difference of 5 cm in height
was approximately equivalent to an age difference of 3
years.Figure 1 FeNO values in the study population (geometric
mean O SD).Moreover, the parameter estimates of the reduced
model without interactions were used to compute pre-
dicted values of FeNO. As an example, Table 5 shows the
results as a function of binary categories for a range of
different values of height for the age category of 50 years.
Discussion
The present study evaluated the relationship between FeNO
values and major influencing factors in a randomly selected
population-based cohort of adults of age 41e63 years. Age,
height, respiratory tract infection, smoking and respiratory
allergy had a statistically significant effect on FeNO. Signif-
icant interactions were found between sex and smoking as
well as respiratory tract infection and smoking, however, the
impact of these interactions was considered negligible.
The pattern of effects on FeNOwas similar to that found in
a previous study in young adults (mean age 34 years) and the
present analysis was designed to compare the patterns
between the two populations of different age range. In the
subjects of younger age (34.5 13.0 y) there was no effect of
age on FeNO, however a significant relationship with sex.13
This relationship was not eliminated by presence of height
as a significant predictor. In the present study, sex only
became significantly associated with FeNO when height was
omitted from the model (data not shown), similar to findings
reported previously.7 It is not clear which factors underly this
difference in the pattern of predictors. The frequencies of
smoking, respiratory allergies and respiratory tract infections
were similar in both studies. However, the sample describedFigure 2 Relationship between log10FeNO and age after
adjustment for allergy, infection, smoking and height.
Table 5 Predicted FeNO values at the age of 50 y.
Smoking e e e e þ þ þ þ
Infection e e þ þ e e þ þ
Allergy e þ e þ e þ e þ
Height [cm]
150 11.0 12.2 12.0 13.2 8.4 9.2 9.1 10.1
160 12.1 13.4 13.2 14.6 9.2 10.2 10.0 11.1
170 13.4 14.8 14.6 16.1 10.2 11.3 11.1 12.3
180 14.8 16.4 16.1 17.8 11.3 12.5 12.2 13.6
190 16.4 18.1 17.8 19.7 12.4 13.8 13.5 15.0
FeNO and influencing factors 717by Dressel et al.13 had been drawn from an outpatient clinic
that was responsible for preventive follow-up measurements
in a broad range of occupationals, whereas the second
sample was derived from a population-based setting. It is
worth to be mentioned that the magnitude of coefficients
regarding height, allergy, infection and smoking was very
similar in both studies. Therefore we consider it likely that
the data reflect true differences in the pattern of factors
influencing FeNO in different age ranges.
In contrast to the data by Dressel et al.,13 however,
a significant influence of age was found in our, partly over-
lapping, age group. There have been conflicting reports
regarding the association between FeNO and age17,18.
Potentially, this relationship is only detectable at very young
ages and in advanced age, whereas it might be negligible
during young adulthood. Possible explanations for an
increase of FeNO with age could include diet19, latent
respiratory inflammation or an increase in peripheral (alve-
olar) NO.20 Irrespective of this we find that in particular the
adjustment for smoking and for height can be performed in
clinical practice in a simple manner as reported previously.
The evidence for a significant independent effect of sex
on FeNO values is inconsistent.11 In our cohort, no significant
impact of sex was found after adjustment for other factors,
especially height. In view of the age range of the present
population sample, one explanation for this observation
might be a change in the hormonal status with increasing
age as a relationship between estrogen/progesterone levels
and exhaled NO has recently been described.21 Further-
more, changes of FeNO in association with premenstrual
asthma have been found22; in fact, estrogen can activate
the endothelial NO synthase in human bronchiolar epithelial
cells in vitro23. However, if the analysis in our cohort was
limited to premenopausal women as compared to men, the
impact of sex still remained non-significant.
The adjusted level of FeNO values in the present data
setwas comparable to results described in previous studies,5,12
however, other authors reported higher values.8,13,18 Beyond
differences in the populations, the use of different NO
analyzers may account for this difference even if they were
calibrated regularly using certified calibration gases and
expiratory flow rate as an important determinant to FeNO
values was carefully checked to be 50 mL/s when the target
mouth pressures were achieved.
Despite studies that have reported comparability of NO
chemiluminescence analyzers,24 the differences between the
mean values reported in various study populations by different
researchers have to be kept in mind.25 There might be furtherdifferences in readings between handheld analyzers and chem-
iluminescence analyzers, as indicated by recalibration factors
being different from one.26 This situation might bear some simi-
larity tothatofbronchial inhalationchallenges.Experienceshows
thatmanycliniciansuseslightlydifferentprotocolsandnebulizers
despite the claim for standardization. This leads to difficulties in
comparing provocative concentrations between different clini-
cians, but the categorization regarding bronchial hyper-
responsivenessmight not be as critically dependent on the use of
different protocols, as far as critical threshold are appropriately
adjusted. These considerations indicate that one still has to be
cautiouswhenreferringtoabsoluteFeNOvalues.Despitethis,our
current andprevious data indicate that the adjustment formajor
influencing factors per se acts similar and thus might be consid-
ered as an implementable set of factors for clinical use.
We conclude that FeNO was affected by infection, age
and height in a random selected study population. These
factors can easily be taken into account and do not signif-
icantly disturb the association of FeNO with respiratory
tract allergies. In current smokers, however, information on
smoking intensity seems to be useful for better adjustment.Acknowledgement
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